Literature DB >> 33841597

Patisiran for advanced heart failure with hereditary transthyretin cardiac amyloidosis.

Makiko Nakamura1, Teruhiko Imamura1, Koichiro Kinugawa1.   

Abstract

We experienced a 78-year-old woman who was diagnosed with hereditary transthyretin cardiac amyloidosis and administered patisiran for advanced heart failure refractory to tafamidis. The levels of N-terminal pro B-type natriuretic peptide and left ventricular mass index decreased following the six-month patisiran treatment without any complications. Patisiran might be a promising disease-modifying drug for hereditary transthyretin cardiac amyloidosis even in its advanced stage, although further evaluation in a large cohort is warranted.
© 2021 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Heart failure with preserved ejection fraction; Transthyretin cardiac amyloidosis; siRNA

Year:  2021        PMID： 33841597      PMCID： PMC8020066          DOI： 10.1016/j.jccase.2021.01.007

Source DB:  PubMed          Journal:  J Cardiol Cases        ISSN： 1878-5409


  8 in total

Review 1.  Treatment of cardiac transthyretin amyloidosis: an update.

Authors:  Michele Emdin; Alberto Aimo; Claudio Rapezzi; Marianna Fontana; Federico Perfetto; Petar M Seferović; Andrea Barison; Vincenzo Castiglione; Giuseppe Vergaro; Alberto Giannoni; Claudio Passino; Giampaolo Merlini
Journal:  Eur Heart J       Date:  2019-12-01       Impact factor: 29.983

2.  Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis.

Authors:  Scott D Solomon; David Adams; Arnt Kristen; Martha Grogan; Alejandra González-Duarte; Mathew S Maurer; Giampaolo Merlini; Thibaud Damy; Michel S Slama; Thomas H Brannagan; Angela Dispenzieri; John L Berk; Amil M Shah; Pushkal Garg; Akshay Vaishnaw; Verena Karsten; Jihong Chen; Jared Gollob; John Vest; Ole Suhr
Journal:  Circulation       Date:  2019-01-22       Impact factor: 29.690

3.  A new staging system for cardiac transthyretin amyloidosis.

Authors:  Julian D Gillmore; Thibaud Damy; Marianna Fontana; Matthew Hutchinson; Helen J Lachmann; Ana Martinez-Naharro; Candida C Quarta; Tamer Rezk; Carol J Whelan; Esther Gonzalez-Lopez; Thirusha Lane; Janet A Gilbertson; Dorota Rowczenio; Aviva Petrie; Philip N Hawkins
Journal:  Eur Heart J       Date:  2018-08-07       Impact factor: 29.983

4.  Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis.

Authors:  David Adams; Alejandra Gonzalez-Duarte; William D O'Riordan; Chih-Chao Yang; Mitsuharu Ueda; Arnt V Kristen; Ivailo Tournev; Hartmut H Schmidt; Teresa Coelho; John L Berk; Kon-Ping Lin; Giuseppe Vita; Shahram Attarian; Violaine Planté-Bordeneuve; Michelle M Mezei; Josep M Campistol; Juan Buades; Thomas H Brannagan; Byoung J Kim; Jeeyoung Oh; Yesim Parman; Yoshiki Sekijima; Philip N Hawkins; Scott D Solomon; Michael Polydefkis; Peter J Dyck; Pritesh J Gandhi; Sunita Goyal; Jihong Chen; Andrew L Strahs; Saraswathy V Nochur; Marianne T Sweetser; Pushkal P Garg; Akshay K Vaishnaw; Jared A Gollob; Ole B Suhr
Journal:  N Engl J Med       Date:  2018-07-05       Impact factor: 91.245

Review 5.  Diagnosis, Prognosis, and Therapy of Transthyretin Amyloidosis.

Authors:  Morie A Gertz; Merrill D Benson; Peter J Dyck; Martha Grogan; Terresa Coelho; Marcia Cruz; John L Berk; Violaine Plante-Bordeneuve; Hartmut H J Schmidt; Giampaolo Merlini
Journal:  J Am Coll Cardiol       Date:  2015-12-01       Impact factor: 24.094

6.  Subtype-Specific Interactions and Prognosis in Cardiac Amyloidosis.

Authors:  Brett W Sperry; Michael N Vranian; Rory Hachamovitch; Hariom Joshi; Asad Ikram; Dermot Phelan; Mazen Hanna
Journal:  J Am Heart Assoc       Date:  2016-03-24       Impact factor: 5.501

Review 7.  Advances in the Treatment of Cardiac Amyloidosis.

Authors:  Ariane Vieira Scarlatelli Macedo; Pedro Vellosa Schwartzmann; Breno Moreno de Gusmão; Marcelo Dantas Tavares de Melo; Otávio Rizzi Coelho-Filho
Journal:  Curr Treat Options Oncol       Date:  2020-04-23

8.  Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy.

Authors:  Mathew S Maurer; Jeffrey H Schwartz; Balarama Gundapaneni; Perry M Elliott; Giampaolo Merlini; Marcia Waddington-Cruz; Arnt V Kristen; Martha Grogan; Ronald Witteles; Thibaud Damy; Brian M Drachman; Sanjiv J Shah; Mazen Hanna; Daniel P Judge; Alexandra I Barsdorf; Peter Huber; Terrell A Patterson; Steven Riley; Jennifer Schumacher; Michelle Stewart; Marla B Sultan; Claudio Rapezzi
Journal:  N Engl J Med       Date:  2018-08-27       Impact factor: 91.245
  8 in total
  1 in total

1.  Combination therapy using tafamidis and neurohormonal blockers for cardiac amyloidosis and a reduced ejection fraction: a case report.

Authors:  Teruhiko Imamura; Toshihide Izumida; Masakazu Hori; Shuhei Tanaka; Koichiro Kinugawa
Journal:  J Int Med Res       Date:  2022-07       Impact factor: 1.573
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.